Neumora Names Joshua Pinto CEO as Berns Moves to Executive Chair
NMRA sits 99% above its 52-week low of $0.83 on light trading volume (0.3× avg).
Summary
Neumora Therapeutics announced that Joshua Pinto, Ph.D. has been appointed CEO, succeeding Paul L. Berns who becomes Executive Chair. The company also named Doron Sagman, M.D. as Chief Medical Officer.
Key Events · Executive and Board Changes · NMRA
-
CEO Transition
Joshua Pinto, Ph.D., currently President, appointed CEO effective August 14, 2026. Paul L. Berns becomes Executive Chair.
-
Board Appointment
Dr. Pinto appointed as Class III director, term expiring at 2029 Annual Meeting.
-
New CMO
Doron Sagman, M.D., FRCPC appointed Chief Medical Officer, bringing 20+ years of clinical development and regulatory experience.
-
Q2 2026 Financials
Net loss of $43.1M, R&D expense $29.3M (down from $38.7M YoY), cash $116.8M expected to fund operations into Q3 2027.
Analysis · NMRA · Life Sciences
Effective August 14, 2026, Neumora announced a leadership transition: Paul L. Berns steps down as CEO to become Executive Chair, and President Joshua Pinto, Ph.D. takes over as CEO and joins the board. The company also appointed Doron Sagman, M.D. as Chief Medical Officer. This comes two months after the Phase 3 failure of its lead depression drug and a 35% workforce reduction, making the leadership change a key governance event for a company in strategic reset.
At the time of this filing, NMRA was trading at $1.65 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $320.5M. The 52-week trading range was $0.83 to $3.65. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.